RESUMO
Cytomegalovirus (CMV) infection is endemic worldwide but its seroprevalence varies widely. The goal of this study was to estimate the age-specific seroprevalence of CMV infection in Belgium based on two cross-sectional serological datasets from 2002 and 2006. The seroprevalence was estimated relying on diagnostic test results based on cut-off values pre-specified by the manufacturers of the tests as well as relying on mixture models applied to continuous pathogen-specific immunoglobulin G antibody titre concentrations. The age-specific seroprevalence of hepatitis A virus (HAV), based on three Belgian cross-sectional serological datasets from 1993, 2002 and 2006, was used as a comparator since individuals acquire lifelong immunity upon recovery, implying an increasing seroprevalence with age. The age group weighted overall CMV seroprevalence derived from the mixture model was 32% (95% confidence interval (CI) 31-34%) in 2002 and 31% (95% CI 30-32%) in 2006. We demonstrated that CMV epidemiology differs from the immunizing infection HAV. This was the first large-scale study of CMV and HAV serial datasets in Belgium, estimating seroprevalence specified by age and birth cohort.
Assuntos
Anticorpos Antivirais/sangue , Infecções por Citomegalovirus/epidemiologia , Citomegalovirus/imunologia , Vírus da Hepatite A/imunologia , Hepatite A/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Idoso , Bélgica/epidemiologia , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Imunoensaio , Imunoglobulina G/sangue , Lactente , Masculino , Pessoa de Meia-Idade , Estudos Soroepidemiológicos , Adulto JovemRESUMO
The Belgian strategic plan to eliminate measles contains several vaccination strategies including routine immunisation programmes and catch-up campaigns. A new expanded programme on immunisation-based survey (2016) assessed the uptake of the recommended measles-mumps-rubella (MMR) vaccine in three different cohorts: toddlers, adolescents and parents of toddlers. A two-stage cluster sampling technique was used to select 875 toddlers (age 18-24 months) and 1250 adolescents (born in 2000) from 107 municipalities in Flanders. After consent of the parent(s), 746 (85.2%) families of toddlers and 1012 (81.0%) families of adolescents were interviewed at home. Measles vaccination coverage was high at 18-24 months (96.2%) and 81.5% were vaccinated at recommended age. Toddlers who had two siblings or a non-working mother or changed vaccinator were more at risk for not being vaccinated. Coverage of the teenager dose reached 93.5% and was lower in adolescents with educational underachievement or whose mother was part-time working or with a non-Belgian background. Only 56.0% of mothers and 48.3% of fathers remembered having received at least one measles-containing vaccine. Although measles vaccination coverage in toddlers meets the required standards for elimination, administration of the teenager dose of MMR vaccine and parent compliance to the recent measles catch-up campaign in Flanders leave room for improvement.
Assuntos
Surtos de Doenças/prevenção & controle , Programas de Imunização/estatística & dados numéricos , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Sarampo/epidemiologia , Sarampo/prevenção & controle , Cobertura Vacinal/estatística & dados numéricos , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Bélgica/epidemiologia , Estudos de Coortes , Feminino , Humanos , Lactente , Masculino , PaisRESUMO
UNLABELLED: The second dose of an MMR vaccine is a catch up for persons who did not receive the first dose or for primary vaccine failures. Catch up doses can be scheduled according to convenience into the program of the country. The second MMR dose is often administered at the age of 5 years, before school entry. Some countries chose to implement the second dose at the age of 10-13 years, as is the case for Belgium. The here presented long-term follow-up of a cohort of children, set up originally to analyze maternal antibodies against vaccine preventable diseases, offers a unique opportunity to evaluate ad interim the current long-interval MMR vaccination schedule in Belgium. After 1 MMR dose at 12 months of age, rubella immunity is almost intact at 5 years of age (94.5 % is seropositive), measles seropositivity scores 86.8 %, and mumps 32 %, measured with ELISA. A seroneutralization (SN) test for mumps antibodies reveals much higher seropositivity rates (88 %). Using a regression model on the log (IgG) titer for all antigens, no influence was found from any of the studied variables, except for girls who had a significantly higher rubella IgG titer (p=0.002) compared to boys. CONCLUSION: The data show considerable susceptibility to mumps and measles in 5-year-old children, confirming a previously conducted seroprevalence study (2006). Both advantages and disadvantages of shortening or enlarging the vaccine schedule are discussed.
Assuntos
Anticorpos Antivirais/sangue , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Sarampo/imunologia , Caxumba/imunologia , Rubéola (Sarampo Alemão)/imunologia , Bélgica/epidemiologia , Pré-Escolar , Estudos de Coortes , Suscetibilidade a Doenças , Feminino , Seguimentos , Humanos , Esquemas de Imunização , Imunização Secundária , Imunoglobulina G/sangue , Masculino , Sarampo/prevenção & controle , Análise Multivariada , Caxumba/prevenção & controle , Rubéola (Sarampo Alemão)/prevenção & controle , Estudos SoroepidemiológicosRESUMO
Despite long-standing two-dose measles-mumps-rubella (MMR) vaccination, measles outbreaks still occur in highly vaccinated European populations. For instance, large measles outbreaks occurred in France (200813), the United Kingdom (201213) and the Netherlands (2012). Based on a multicohort model approach, using spatial serological survey data, MMR vaccination coverage data and data on social contacts, we found effective reproduction numbers significantly higher than 1 for measles in Belgium. This indicates that at one of the expected re-introductions, a measles outbreak is likely to spread, especially when it occurs during school term. The predicted average effective reproduction number increased over a 30-year time span from 1.3 to 2.2 and from 1.9 to 3.2 for basic reproduction numbers of 12 and 18, respectively. The expected relative measles incidence was highest in infants under one year of age, in adolescents and young adults. In conclusion, gradually increasing proportions of susceptible adolescents and young adults provide through their highly active social life an avenue for measles to resurge in large outbreaks upon re-introduction in Belgium, especially during school terms. Infants form an important vulnerable group during future measles outbreaks.
Assuntos
Surtos de Doenças/prevenção & controle , Sarampo/prevenção & controle , Medição de Risco , Vacinação/estatística & dados numéricos , Adolescente , Fatores Etários , Bélgica/epidemiologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Sarampo/epidemiologia , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Modelos Estatísticos , Países Baixos/epidemiologia , Estudos Soroepidemiológicos , Análise Espacial , Reino Unido/epidemiologia , Adulto JovemRESUMO
Hepatitis B virus (HBV) can be eliminated by effective universal vaccination. In Belgium, a free-of-charge HBV vaccination programme in infants with catch-up in adolescents was introduced in 1999. To evaluate the effects in <20-year-olds, seroprotection (anti-HBs >11 mIU/ml, according to the assay) and markers of infection (anti-HBc, HBsAg) were assessed in 2443 residual sera collected 7-8 years after implementation of the programme. The maximal prevalence of a solely anti-HBs seroprotective ('vaccinated') serostatus was 82·9% at age 1 year and 60·5% at age 13 years. A clear increase was found in age cohorts targeted by the campaign after a similar serosurvey conducted 4 years earlier. The prevalence of HBV infection remained unchanged at a low level (1·8% in 2006) similar to pre-vaccination data (1993-1994). We conclude that universal HBV vaccination has achieved overall high levels of vaccine-induced immunity, despite regional variations, which may give rise to pockets of susceptible young adults in the future.
Assuntos
Anticorpos Anti-Hepatite B/sangue , Vacinas contra Hepatite B/uso terapêutico , Vírus da Hepatite B/imunologia , Hepatite B/prevenção & controle , Vacinação em Massa/estatística & dados numéricos , Adolescente , Bélgica/epidemiologia , Criança , Pré-Escolar , Feminino , Hepatite B/epidemiologia , Humanos , Esquemas de Imunização , Lactente , Masculino , Estudos Soroepidemiológicos , Adulto JovemRESUMO
In Belgium, rotavirus vaccination has been recommended and partially reimbursed since October 2006. Through a retrospective survey in 2012, we estimated the coverage rate of the rotavirus vaccination in Flanders among infants born in 2010. Using a standardised questionnaire, 874 families were interviewed at home, collecting information on demographic characteristics, socio-economic background and documented vaccination history (updated from medical files and vaccination database, if needed). Adherence to the recommended age for vaccination (8, 12 and 16 weeks) was also assessed. The coverage rate for two doses of rotavirus vaccination was 92.2% (95% confidence interval: 90.2-93.8). Respectively 31.7% and 10.1% of the children received their first and second dose at the recommended age. Incomplete vaccination was often a deliberate choice of the parents. Only eight children (1%) were vaccinated after the maximum age of 26 weeks. Factors identified by multiple logistic regression as related to incomplete vaccination were: living in the province of Antwerp, unemployed mother, and three or more older siblings in the household. Four years after introduction, the coverage rates were surprisingly high for a vaccine that is not fully reimbursed and not readily available in the vaccinator's fridge, which is the case for the other recommended infant vaccines.
Assuntos
Programas de Imunização , Esquemas de Imunização , Infecções por Rotavirus/prevenção & controle , Vacinas contra Rotavirus/administração & dosagem , Vacinação/estatística & dados numéricos , Bélgica , Análise por Conglomerados , Intervalos de Confiança , Características da Família , Feminino , Humanos , Lactente , Entrevistas como Assunto , Modelos Logísticos , Masculino , Características de Residência/estatística & dados numéricos , Estudos Retrospectivos , Fatores Socioeconômicos , Inquéritos e QuestionáriosRESUMO
Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vaccination strategies. Samples from national population serum banks were collected, tested for mumps IgG antibodies and standardized for international comparisons. A comparative analysis between countries was undertaken using age-specific mumps seroprevalence data and information on reported mumps incidence, vaccine strains, vaccination programmes and vaccine coverage 5-12 years after sera collection. Mean geometric mumps antibody titres were lower in mumps outbreak countries [odds ratio (OR) 0·09, 95% confidence interval (CI) 0·01-0·71)]. MMR1 vaccine coverage ⩾95% remained protective in a multivariable model (P < 0·001), as did an interval of 4-8 years between doses (OR 0·08, 95% CI 0·01-0·85). Preventing outbreaks and controlling mumps probably requires several elements, including high-coverage vaccination programmes with MMR vaccine with 4-8 years between doses.
Assuntos
Anticorpos Antivirais/sangue , Surtos de Doenças , Vacina contra Caxumba , Vírus da Caxumba/imunologia , Caxumba/epidemiologia , Caxumba/imunologia , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Criança , Pré-Escolar , Europa (Continente)/epidemiologia , Feminino , Humanos , Esquemas de Imunização , Incidência , Lactente , Masculino , Pessoa de Meia-Idade , Estudos Soroepidemiológicos , Adulto JovemRESUMO
Susceptibility to vaccine-preventable diseases in Belgium in 2006 was estimated from a serum survey. Immunoglobulins against measles, mumps, rubella (MMR) and diphtheria at all available ages (1-65 years), and against tetanus in >40-year-olds, were measured by ELISA. Age-standardized overall seronegativity for MMR was low (3·9%, 8·0%, 10·4%, respectively). However, the World Health Organization's targets for measles elimination were not met in 5- to 24-year-olds and about 1 in 7 women at childbearing age (15-39 years) were seronegative for rubella. In adults >40 years, tetanus immunity (87·2%, >0·16 IU/ml) largely exceeded diphtheria immunity (20-45%, >0·1 IU/ml). Despite free universal vaccination against MMR for more than 20 years and against diphtheria and tetanus for almost 60 years, our study revealed specific age groups remaining at risk for infection with these pathogens.
Assuntos
Difteria/epidemiologia , Sarampo/epidemiologia , Caxumba/epidemiologia , Rubéola (Sarampo Alemão)/epidemiologia , Tétano/epidemiologia , Adolescente , Adulto , Fatores Etários , Idoso , Anticorpos Antibacterianos/sangue , Anticorpos Antivirais/sangue , Bélgica/epidemiologia , Criança , Pré-Escolar , Difteria/prevenção & controle , Vacina contra Difteria e Tétano/administração & dosagem , Vacina contra Difteria e Tétano/imunologia , Feminino , Humanos , Lactente , Masculino , Sarampo/prevenção & controle , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Vacina contra Sarampo-Caxumba-Rubéola/imunologia , Pessoa de Meia-Idade , Caxumba/prevenção & controle , Rubéola (Sarampo Alemão)/prevenção & controle , Estudos Soroepidemiológicos , Tétano/prevenção & controle , Adulto JovemRESUMO
BACKGROUND: In the context of precision medicine and in response to the highly needed capacity of rapid interventions towards new infectious diseases and pandemic outbreaks, intradermal immunization is gaining increased attention. However, the currently used Mantoux technique for ID injection is difficult to standardize and requires training, especially when used in children. To allow determining the maximum penetration depth and needle characteristics for the development of a platform of medical devices suited for intradermal injection, VAX-ID® and to ensure an accurate ID injection in children, the epidermal and dermal thickness at the proximal ventral and dorsal forearm (PVF & PDF) and at the deltoid region in children aged 8â¯weeks to 18â¯years were assessed. The lateral part of the upper leg was assessed as well in children aged 8â¯weeks to 2â¯years since it is a commonly used injection site in this population. MATERIALS & METHODS: Mean thickness of the PVF, PDF, lateral part of the upper leg and deltoid were measured using high-frequency ultrasound. Association with gender, age and BMI was assessed using Mann-Whitney U Test, Spearman correlation and Wilcoxon Signed Ranks Test, respectively. RESULTS: Results showed an overall mean skin thickness of 0.99â¯mm (SD: 0.14â¯mm) at the PVF, 1.20â¯mm (SD: 0.17) at the PDF, 1.28â¯mm (SD: 0.16) at the lateral part of the upper leg and increasing to 1.32â¯mm (0.25) at the deltoid region. Age and BMI correlated significantly (pâ¯<â¯0.001) with skin thickness at all investigated body sites. Gender did not affect skin thickness in the investigated population. CONCLUSION: Significant differences in skin thickness at the PVF, PDF and deltoid region were seen according to age and BMI. An optimal needle length of 0.7â¯mm is advised to guarantee intradermal injection in children at all investigated injection sites. (NCT02727114).
Assuntos
Derme/anatomia & histologia , Epiderme/anatomia & histologia , Pele/anatomia & histologia , Adolescente , Fatores Etários , Índice de Massa Corporal , Criança , Pré-Escolar , Derme/diagnóstico por imagem , Epiderme/diagnóstico por imagem , Feminino , Humanos , Lactente , Injeções Intradérmicas/métodos , Masculino , Agulhas , Fatores Sexuais , Pele/diagnóstico por imagem , Ultrassonografia , Vacinação/métodosRESUMO
BACKGROUND: Although intramuscular (IM) injection is still the most preferred method for vaccination, intradermal (ID) delivery may have several advantages over intramuscular and subcutaneous (SC), including an improved immune response and antigen dose sparing effect. However it is currently limited due to the difficulty in standardizing the injection technique often based on the Mantoux technique. Difficulties encountered using the Mantoux technique could be overcome by the use of alternative ID delivery systems that confer more uniform and standardized procedures. The aim of this study was to evaluate the performance of a newly developed intradermal injection device, VAX-ID™, via a proof-of-concept to assess the immunogenicity of a commercially available hepatitis B booster vaccination in healthy hepatitis B pre-immunised subjects. Additionally, device safety and tolerability was evaluated. MATERIALS AND METHODS: Three different routes of administration were compared over 4 groups, each receiving hepatitis B vaccine antigen: (1) standard IM injection in the deltoid region (HBVAXPRO® 10⯵g/1â¯ml), (2) ID injection in the proximal posterior area of the forearm according to the Mantoux technique, (3) with VAX-ID™ in one forearm, or (4) with VAX-ID™ in both forearms. For ID injections 0.11â¯cc, of which 0.01â¯cc is overfill, was drawn from a vial containing HBVAXPRO® 40⯵g/1â¯ml. Immunogenicity and safety were followed-up at day 0, 14, 30 and 210. RESULTS: A total of 48 subjects were included. All subjects showed an anamnestic response at 14â¯days post booster vaccination. Elevated titres persisted until end of follow-up at day 210. For the ID groups a 3 fold higher immune response at day 14 and day 30 was recorded compared to IM group. Local adverse events were more reported for ID compared to IM. CONCLUSIONS: The investigated ID injection device VAX-ID™ proves to be a good alternative to offer ID vaccination.
Assuntos
Sistemas de Liberação de Medicamentos/instrumentação , Segurança de Equipamentos , Vacinas contra Hepatite B/administração & dosagem , Vacinação/instrumentação , Vacinação/métodos , Adolescente , Adulto , Vias de Administração de Medicamentos , Feminino , Anticorpos Anti-Hepatite/sangue , Hepatite B/prevenção & controle , Vacinas contra Hepatite B/imunologia , Humanos , Imunização Secundária , Imunogenicidade da Vacina , Memória Imunológica , Injeções Intradérmicas , Injeções Intramusculares , Masculino , Estudo de Prova de Conceito , Adulto JovemRESUMO
BACKGROUND: Intradermal immunization is gaining increased attention due to multiple factors: (1) intradermal (ID) vaccination has been shown to induce improved immunogenicity compared to intramuscular (IM) vaccination; (2) ID vaccination has been shown to have a dose-sparing potential over IM leading to a reduced vaccine cost and an increased availability of vaccines worldwide. However, the currently used Mantoux technique for ID injection is difficult to standardize and requires training. The aim of the study was (1) to assess the epidermal and dermal thickness at the proximal ventral and dorsal forearm (PVF & PDF) and deltoid in adults aged 18-65years (2) to determine the maximum penetration depth and needle characteristics for the development of a platform of medical devices suited for intradermal injection, VAX-ID™. MATERIALS AND METHODS: Mean thickness of the PVF, PDF and deltoid were measured using high-frequency ultrasound of healthy adults aged 18-65years. Correlation with gender, age and BMI was assessed using Mann-Whitney U Test, Spearman correlation and Wilcoxon Signed Ranks Test, respectively. RESULTS: Results showed an overall mean skin thickness of 1.19mm (0.65-1.55mm) at the PVF, 1.44mm (0.78-1.84mm) at the PDF, and 2.12mm (1,16-3.19mm) at the deltoid. Thickness of PVF & PDF and deltoid were significantly different for men vs women (pmean<0.001, <0.001, <0.001, and pmin<0.001, 0.012, <0.001, respectively). A significant association was found for age at the deltoid region (p<0.001). Skin thickness for PVF, PDF & deltoid was significantly associated to BMI (p<0.001). CONCLUSION: Significant differences in skin thickness were seen for the PVF, PDF and deltoid region for gender, and BMI. Age only influenced the skin thickness at deltoid region. A needle length of 1.0mm is best option for intradermal injection at the dorsal forearm (NCT02363465).
Assuntos
Pele/anatomia & histologia , Pele/diagnóstico por imagem , Ultrassonografia/métodos , Adolescente , Adulto , Idoso , Análise de Variância , Pesos e Medidas Corporais/métodos , Derme/anatomia & histologia , Derme/diagnóstico por imagem , Epiderme/anatomia & histologia , Epiderme/diagnóstico por imagem , Feminino , Voluntários Saudáveis , Humanos , Injeções Intradérmicas/métodos , Injeções Intradérmicas/normas , Masculino , Pessoa de Meia-Idade , Vacinação/métodos , Vacinação/normas , Adulto JovemRESUMO
Vaccination schedules for under-five children in the EU member states differ markedly, mainly as a consequence of differences in programme organization, decision making and history, and to a limited extent by epidemiological differences. There is little willingness towards unification since little evidence exists to prefer one schedule over the others, but the differences might impact on public confidence. Monitoring key determinants influencing individual decision making on immunization ('soft impacts') is thus as important as other existing monitoring systems of the 'hard' impacts of immunization programmes, and both should focus on the impact of these schedule differences. Harmonization of vaccination schedules is not the main issue, but the reasons behind the differences should be explained in an understandable and coherent way to the public. Scientists and advisory bodies should look over the country borders and communicate any crucial information, in order to improve scientific consensus on immunization schedules and programmes. These were the main conclusions of a members' experts panel of the European network of independent science advisory bodies on health (EuSANH), at a workshop in November 2012.
Assuntos
Política de Saúde , Esquemas de Imunização , Vacinas/administração & dosagem , União Europeia , HumanosRESUMO
To inform current and future vaccination strategies, we describe the seroepidemiology of hepatitis B virus (HBV) infection in ten representative European countries using standardized serology that allowed international comparisons. Between 1996 and 2003, national serum banks were compiled by collecting residual sera or by community sampling; sera were then tested by each country using its preferred enzyme immunoassays and testing algorithm, and assay results were standardized. Information on current and past HBV vaccination programmes in each country was also collected. Of the ten countries, six reported low levels (<3%) of antibodies against HBV core antigen (anti-HBc). Of the eight countries testing for HBV surface antigen (HBsAg), the highest prevalence was reported in Romania (5.6%) and in the remaining seven countries prevalence was <1%. Universal HBV vaccination programmes had been established in seven countries as recommended by the World Health Organization, but the seroprevalence of antibodies against HBsAg (anti-HBs) was lower than the reported vaccine coverage in three countries. Regular serological surveys to ascertain HBV status within a population, such as reported here, provide important data to assess the need for and to evaluate universal HBV vaccination programmes.
Assuntos
Hepatite B/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Criança , Pré-Escolar , Europa (Continente)/epidemiologia , Feminino , Hepatite B/sangue , Anticorpos Anti-Hepatite B/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Soroepidemiológicos , Adulto JovemRESUMO
Testing humans for infectious diseases is often done by assessing the presence or absence of disease-specific antibodies in serum samples. For feasibility and economical reasons, these sera are often tested for more than one antigen. Studying diseases with similar transmission routes can govern new insights for disease dynamics. We use flexible marginal and conditional models to model multisera data on the Varicella-Zoster virus and the Parvo B19-virus in Belgium. Next form the derivation of the age-dependent marginal force of infection (FOI), we introduce new epidemiological parameters: the age-dependent joint and conditional FOI. These parameters allow us to study the association among the occurrence and acquisition of both infections. Furthermore, we show how to test for association and whether the infection-specific age-dependent FOI curves are proportional and consequently whether separable mixing in the population holds.
Assuntos
Doenças Transmissíveis/diagnóstico , Modelos Estatísticos , Estudos Soroepidemiológicos , Bélgica , Doenças Transmissíveis/sangue , Estudos Epidemiológicos , Herpesvirus Humano 3/patogenicidade , Humanos , Parvovirus B19 Humano/patogenicidade , VirulênciaRESUMO
As aluminium in vaccines has been associated with the incidence of local side effects occurring after vaccination, this observer-blind randomised clinical trial was designed to evaluate the effect of lowering the aluminium content of a combined reduced-antigen-content dTpa vaccine on immunogenicity and safety when administered to healthy adolescents aged 10-18 years. A total of 647 subjects were enrolled, 224 (35%) received a dTpa formulation with 0.5 mg aluminium, 209 (32%) a formulation with 0.3 mg aluminium and 214 (33%) a formulation with 0.133 mg aluminium. One month after boostering, all subjects were seroprotected against diphtheria and tetanus toxoids. All subjects were seropositive for anti-FHA and anti-PRN but 4% of the initially seronegatives in both reduced aluminium groups did not seroconvert for anti-PT. Booster responses did not differ significantly between groups for any antibody, but post booster vaccination anti-PT GMC's differed significantly between groups and decreased when vaccine aluminium content decreased. No clear difference between study groups in local or general side effects was demonstrated. The most frequently reported symptoms after vaccination were injection site pain (89.5-90.7%), fatigue (42.1-47.4%) and headache (41.1-45.1%). This study showed that the aluminium content has a specific influence on the immunogenicity of this dTpa vaccine.